About Phenazine biosynthesis-like domain-containing protein
Phenazine biosynthesis-like domain-containing protein (PBLD) is a protein
from Homo sapiens identified by UniProt accession
P30039, 288 residues long.
MolForge cross-references it against 0 known binders and
64 disease associations.
Target properties
| Protein name | Phenazine biosynthesis-like domain-containing protein |
|---|
| UniProt accession | P30039 |
|---|
| Gene | PBLD |
|---|
| Organism | Homo sapiens |
|---|
| Length | 288 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (64)
Diseases linked to this target (Open Targets).
- optic disc size measurement · score 0.37
- protein measurement · score 0.31
- optic disc measurement · score 0.26
- retinal layer thickness measurement · score 0.24
- optic cup area measurement · score 0.20
- retinal nerve fibre layer thickness measurement · score 0.17
- hepatocellular carcinoma · score 0.09
- body height · score 0.07
- metabolite measurement · score 0.06
- neoplasm · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P30039-F1 | alphafold | PREDICTED | 95.40 | — |
Amino-acid sequence (288 residues)
MKLPIFIADA FTARAFRGNP AAVCLLENEL DEDMHQKIAR EMNLSETAFI RKLHPTDNFA QSSCFGLRWF TPASEVPLCG HATLASAAVL FHKIKNMNST LTFVTLSGEL RARRAEDGIV LDLPLYPAHP QDFHEVEDLI KTAIGNTLVQ DICYSPDTQK LLVRLSDVYN RSFLENLKVN TENLLQVENT GKVKGLILTL KGEPGGQTQA FDFYSRYFAP WVGVAEDPVT GSAHAVLSSY WSQHLGKKEM HAFQCSHRGG ELGISLRPDG RVDIRGGAAV VLEGTLTA
Explore Phenazine biosynthesis-like domain-containing protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets